Consolidated Trial Balance
Explain each group balance through translated inputs, the reviewed closing CTA effect, retained elimination and reversal history, supported allocation entries and approved top-sides.
Resolve reciprocal source differences before posting a balanced consolidation-layer elimination.
3 stages · 2 approvals
Follow the process from start to finish. Select a step to see who acts and what changes.
Consolidation Manager: Independently accept a frozen submitted revision only after balance, source period, currency and mapping checks. Count distinct required entities with current Accepted submissions; Submitted and Imported do not satisfy readiness.
Independently accept a frozen submitted revision only after balance, source period, currency and mapping checks.Consolidation Manager: Accept or reject SubsidiaryTrialBalances
Approval waits for the consolidation manager.
Consolidation Manager: Match reciprocal source identities once, resolve differences explicitly and independently approve balanced elimination proposals. A manual proposal prepared by the manager requires Group Controller / Corporate CFO review. Posting affects the consolidation layer only.
Match reciprocal source identities once, resolve differences explicitly and independently approve balanced elimination proposals.Elimination approval waits for the consolidation manager or group controller / corporate cfo.
Consolidation Manager: Build one result set from the same complete run. Include the closing translation adjustment, posted elimination history and its linked reversals, and approved balanced adjustment and allocation effects. Validate account totals, entity coverage and movement reconciliations before review.
Build one result set from the same complete run.| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
SubsidiaryTrialBalances, TrialBalanceLines
IntercompanyTransactions, ICReconciliation, ICDisputes, Eliminations, EliminationLines
A reconciliation preserves each source side and the amount allocated to it. Reversing the from/to direction cannot make a second independent pair. Stable source identities protect against replay and overlapping matching workers. The original subsidiary postings remain unchanged by the group-layer elimination.
A difference inside tolerance still needs its configured disposition. If a corrective entry is required, create a separately balanced reviewed proposal. Never force unequal amounts into a journal by silently reducing one subsidiary’s balance. A missing counterpart remains missing until source evidence or an authorised correction establishes the result.
Posted eliminations retain their lines and reviewers. A changed source balance cannot edit that history; prepare a reversal and reviewed replacement within an authorised open financial revision. A material unresolved dispute prevents group publication even if other pairs have finished.
| Stage | Records | Effect |
|---|---|---|
| 1 Accept subsidiary balances | SubsidiaryTrialBalancesTrialBalanceLines | Independently accept a frozen submitted revision only after balance, source period, currency and mapping checks. |
| 2 Resolve and eliminate intercompany | IntercompanyTransactionsICReconciliationICDisputesEliminationsEliminationLines | Match reciprocal source identities once, resolve differences explicitly and independently approve balanced elimination proposals. |
| 3 Build consolidated results | ConsolidationRunsConsolidatedTrialBalanceConsolidatedFinancials | Build one result set from the same complete run. |
Explain each group balance through translated inputs, the reviewed closing CTA effect, retained elimination and reversal history, supported allocation entries and approved top-sides.
| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
Compare reviewed period and cumulative group results with the approved parent and non-controlling allocation.
| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
Reconcile group assets, liabilities and equity at the selected published revision.
| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
Explain cash changes with reviewed operating, investing, financing, currency and non-cash movement evidence.
| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
Tie opening equity and translation adjustment through supported movements to the closing balances.
| Balance Number | Consolidation Account | Translated Subtotal USD | CTAAmount USD | Eliminations USD |
|---|---|---|---|---|
| CTB-59395 | CCA-6184 | 330 | 870 | 110 |
| CTB-41681 | CCA-8430 | 960 | 390 | 270 |
| CTB-45811 | CCA-5800 | 160 | 200 | 890 |
| CTB-86159 | CCA-5223 | 840 | 200 | 280 |
| CTB-65204 | CCA-9916 | 870 | 310 | 280 |
| CTB-52854 | CCA-1374 | 220 | 60 | 570 |
Identify reciprocal balances, remaining differences and the reviewed elimination or exception disposition.
Proto cannot override entity scope, approve its own preparation, invent missing accounting evidence or publish on an unreviewed calculation. Financial decisions remain with the authorised people.
Bring accepted subsidiary balances and approved translation inputs into one complete group calculation.
6 stages · 3 approvals
Carry the approved effective ownership basis into translated, allocated group results.
4 stages · 2 approvals
Turn the reviewed financial revision into a locked published pack and a controlled audit trail.
4 stages · 2 approvals
Create your ERP.AI account and get started with Proto.
We use essential cookies to run the site and optional cookies for features, analytics, and relevant content. See Cookie policy
We use cookies to enhance your experience, analyze site traffic, and serve relevant content. By clicking "Accept All," you agree to our use of cookies. You can customize your preferences at any time.
Learn more about how we use cookiesThese cookies are required for the website to function properly. They ensure security, enable basic features like page navigation, and store user session data. You cannot disable these cookies.
These cookies enable additional features that enhance your experience, such as live chat, video playback, personalized content recommendations, and remembering user preferences.
These cookies help us understand how visitors interact with our site by collecting anonymous usage data. This allows us to measure performance, detect issues, and continuously improve the user experience.
These cookies allow us and advertising partners, including X, to deliver ads tailored to your interests. They track browsing habits across sites to provide relevant advertising and measure ad effectiveness.